Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at Cantor Fitzgerald cut their FY2024 EPS estimates for Oncolytics Biotech in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($0.42) per share for the year, down from their prior estimate of ($0.36). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share.
Separately, Raymond James raised shares of Oncolytics Biotech to a "moderate buy" rating in a report on Thursday.
Read Our Latest Stock Analysis on ONC
Oncolytics Biotech Stock Up 0.7 %
Oncolytics Biotech stock traded up C$0.01 on Monday, hitting C$1.39. 17,762 shares of the stock traded hands, compared to its average volume of 70,788. The business's fifty day simple moving average is C$1.50 and its 200 day simple moving average is C$1.45. Oncolytics Biotech has a 1 year low of C$1.15 and a 1 year high of C$2.32. The firm has a market cap of C$106.84 million, a P/E ratio of -3.63 and a beta of 1.35. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
